Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes

British Journal of Diabetes
doi 10.15277/bjd.2016.092
Full Text
Abstract

Available in full text

Date
Authors
Publisher

ABCD Diabetes Care, Ltd.

Related search

SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient With Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes

Internal Medicine
Internal MedicineMedicine
2020English

Effective SGLT2 Inhibitor for Patient With Type 2 Diabetes Mellitus (T2DM) and Depression

2020English

SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
2016English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

Ertugliflozin: A New SGLT2 Inhibitor for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Portion Control Plate for Weight Loss in Obese Patients With Type 2 Diabetes Mellitus

Archives of Internal Medicine
2007English

Weight Loss Promoted by the Intra-Oral Alimentary Satiety Device in a Morbidly Obese Patient

RGO Revista Gaucha de Odontologia
Dentistry
2015English

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis

Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy